Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To determine the respective efficacy of quetiapine and rivastigmine for agitation in people with dementia in institutional care and to evaluate these treatments with respect to change in cognitive performance. DESIGN: Randomised double blind (clinician, patient, outcomes assessor) placebo controlled trial. SETTING: Care facilities in the north east of England. PARTICIPANTS: 93 patients with Alzheimer's disease, dementia, and clinically significant agitation. INTERVENTION: Atypical antipsychotic (quetiapine), cholinesterase inhibitor (rivastigmine), or placebo (double dummy). MAIN OUTCOME MEASURES: Agitation (Cohen-Mansfield agitation inventory) and cognition (severe impairment battery) at baseline and at six weeks and 26 weeks. The primary outcome was agitation inventory at six weeks. RESULTS: 31 patients were randomised to each group, and 80 (86%) started treatment (25 rivastigmine, 26 quetiapine, 29 placebo), of whom 71 (89%) tolerated the maximum protocol dose (22 rivastigmine, 23 quetiapine, 26 placebo). Compared with placebo, neither group showed significant differences in improvement on the agitation inventory either at six weeks or 26 weeks. Fifty six patients scored > 10 on the severe impairment battery at baseline, 46 (82%) of whom were included in the analysis at six week follow up (14 rivastigmine, 14 quetiapine, 18 placebo). For quetiapine the change in severe impairment battery score from baseline was estimated as an average of -14.6 points (95% confidence interval -25.3 to -4.0) lower (that is, worse) than in the placebo group at six weeks (P = 0.009) and -15.4 points (-27.0 to -3.8) lower at 26 weeks (P = 0.01). The corresponding changes with rivastigmine were -3.5 points (-13.1 to 6.2) lower at six weeks (P = 0.5) and -7.5 points (-21.0 to 6.0) lower at 26 weeks (P = 0.3). CONCLUSIONS: Neither quetiapine nor rivastigmine are effective in the treatment of agitation in people with dementia in institutional care. Compared with placebo, quetiapine is associated with significantly greater cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Functional Assessment Staging (FAST)
(2001) · Management of Dementia · doi:10.3109/9780203213896-33 · Cited by 1,023
A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
Feldman, H., Gauthier, S., Hecker, J., Vellas, B., Subbiah, P., Whalen, E., & the Donepezil MSAD Study Investigators Group* (2001) · Neurology · doi:10.1212/wnl.57.4.613 · Cited by 601
To: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
(2001) · Neurology · doi:10.1212/wnl.57.11.2153-a · Cited by 489
Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.54 · Cited by 422
Ballard, C., Holmes, C., McKeith, I., Neill, D., O’Brien, J., Cairns, N., Lantos, P., Perry, E., Ince, P., & Perry, R. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.7.1039 · Cited by 315
Self-citationReceptor pharmacology of neuroleptics: relation to clinical effects.
Richelson, E. (1999) · PubMed · Cited by 306
COMMITTEE ON SAFETY OF MEDICINES
SCOWEN, E. (1978) · British Journal of Anaesthesia · doi:10.1093/bja/50.12.1270-a · Cited by 296
Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up
McShane, R., Keene, J., Gedling, K., Fairburn, C., Jacoby, R., & Hope, T. (1997) · BMJ · doi:10.1136/bmj.314.7076.266 · Cited by 267
Self-citationIncreased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs
Perry, E. K., Kilford, L., Lees, A. J., Burn, D. J., & Perry, R. H. (2003) · Annals of Neurology · doi:10.1002/ana.10639 · Cited by 231
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings, J. L. (2003) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00004 · Cited by 202
Saxton, J., McGonigle-Gibson, K. L., Swihart, A. A., & Miller, V. J. (1990) · Psychological Assessment · doi:10.1037//1040-3590.2.3.298 · Cited by 195
Schmitt, F. A., Ashford, W., Ernesto, C., Saxton, J., Schneider, L. S., Clark, C. M., Ferris, S. H., Mackell, J. A., Schafer, K., & Thal, L. J. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00008 · Cited by 149
Survey of neuroleptic prescribing in residents of nursing homes in Glasgow: Table 1
McGrath, A. M., & Jackson, G. A. (1996) · BMJ · doi:10.1136/bmj.312.7031.611 · Cited by 133
Schmitt, F. A., Ashford, W., Ernesto, C., Saxton, J. A., Schneider, L., Clark, C. M., Ferris, S. H., Mackell, J. A., Schafer, K. A., & Thal, L. J. (1997) · PubMed · Cited by 111
Ballard, C., Fossey, J., Chithramohan, R., Howard, R., Burns, A., Thompson, P., Tadros, G., & Fairbairn, A. (2001) · BMJ · doi:10.1136/bmj.323.7310.426 · Cited by 107
Self-citationAssessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties.
Cohen‐Mansfield, J. (1995) · PubMed · Cited by 85
Treating behavioural and psychological signs in Alzheimer's disease
Ballard, C., & O'Brien, J. (1999) · BMJ · doi:10.1136/bmj.319.7203.138 · Cited by 76
Self-citationCognitive and Behavioral Effects of Quetiapine in Alzheimer Disease Patients
Scharre, D. W., & Chang, S. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200204000-00011 · Cited by 54
Coffey, E. T., Åkerman, K. E. O., & Courtney, M. J. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00335-2 · Cited by 50
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings, J. L. (2003) · American Journal of Geriatric Psychiatry · doi:10.1176/appi.ajgp.11.2.131 · Cited by 33
Fleming, K., Thyrum, P. T., Yeh, C., Vargo, D. L., & Potkin, S. G. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00011 · Cited by 12
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings, J. L. (2004) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.2.2.239 · Cited by 8
Cited by
Dementia prevention, intervention, and care
Livingston, G., Sommerlad, A., Orgeta, V., Costafreda, S. G., Huntley, J., Ames, D., Ballard, C., Banerjee, S., Burns, A., Cohen-Mansfield, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31363-6 · Cited by 6,072
Self-citationSchneider, L. S., Dagerman, K. S., & Insel, P. (2005) · JAMA · doi:10.1001/jama.294.15.1934 · Cited by 1,671
“After the trials to be included were identified, we extracted or calculated total drug and placebo exposure duration (patient-years of treatment) after noticing that this information could be obtained from several sources, including a presentation by the FDA,(23) a manuscript under review,(31) a “letter to health care…”
BackgroundMethodSchneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Self-citation
Metadata
- Authors
- Ballard, C., Margallo-Lana, M., Juszczak, E., Douglas, S., Swann, A., Thomas, A., O'Brien, J., Everratt, A., Sadler, S., Maddison, C., Lee, L., Bannister, C., Elvish, R., & Jacoby, R.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2005-02-18
- Volume
- 330
- Issue
- 7496
- Pages
- 874
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2114293963
- Cited by
- 315
- References
- 25
- FWCI
- 18.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.bmj.org/licenses/tdm/1.0/terms-and-conditions.html (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.